/
Other
Hearing Loss
15
Pipeline Programs↗
62
Active Trials↗
31
Companies Involved↗
Hearing Loss is an emerging landscape with 15 programs across 31 companies. The most active players are Sound Pharmaceuticals, Incorporated. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical10
Cisplatin
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
TJ0113
Hangzhou PhecdaMed Co., Ltd.
Ginaton
Peking University People's Hospital
Dexamethasone or Methylprednisolone
Second Affiliated Hospital, School of Medicine, Zhejiang University
Intracochlear Application of VSF1.01
Hannover Medical School
Phase 12
Phase 22
Phase 31
Approved
No programs
Analysis
Trial Status
139
clinical trials
Completed52 · 37%
Recruiting29 · 21%
Not yet recruiting23 · 17%
Terminated11 · 8%
Unknown status10 · 7%
Active, not recruiting8 · 6%
Other6 · 4%
Clinical Trials
Trial Activity
139 trials
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)